Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components

Caligiuri, Alessandra; Parola, Maurizio; Marra, Fabio; Cannito, Stefania; Gentilini, Alessandra

doi:10.20517/2394-5079.2023.23

Cited by 1 publication

(1 citation statement)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study confirmed that MASLD exacerbates cholangitis and promotes iCCA in mice [109]. iCCA is characterized by a highly reactive desmoplastic stroma with a complex mechanism underlying the mutual interactions between tumor cells and the stromal compartment [110]. Although the pathogenic mechanisms of MASLD-associated iCCA have not been elucidated, iCCA development in patients with metabolic syndrome is characterized by osteopontin overexpression in the tumor stroma [111].…”

Section: Masld-associated Iccamentioning

confidence: 91%

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Takahashi,

Dungubat,

Kusano

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the livers of patients without a history of alcohol abuse. It is classified as either simple steatosis (nonalcoholic fatty liver) or nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and hepatocellular carcinoma (HCC). Recently, it was suggested that the terms “metabolic dysfunction-associated steatotic liver disease (MASLD)” and “metabolic dysfunction-associated steatohepatitis (MASH)” should replace the terms “nonalcoholic fatty liver disease (NAFLD)” and “nonalcoholic steatohepatitis (NASH)”, respectively, with small changes in the definitions. MASLD, a hepatic manifestation of metabolic syndrome, is rapidly increasing in incidence globally, and is becoming an increasingly important cause of HCC. Steatohepatitic HCC, a histological variant of HCC, is characterized by its morphological features resembling non-neoplastic steatohepatitis and is closely associated with underlying steatohepatitis and metabolic syndrome. Variations in genes including patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily 2 (TM6SF2), and membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7) are associated with the natural history of MASLD, including HCC development. The mechanisms of HCC development in MASLD have not been fully elucidated; however, various factors, including lipotoxicity, inflammation, reactive oxygen species, insulin resistance, and alterations in the gut bacterial flora, are important in the pathogenesis of MASLD-associated HCC. Obesity and MASLD are also recognized as risk factors for hepatocellular adenomas, and recent meta-analyses have shown an association between MASLD and intrahepatic cholangiocarcinoma. In this review, we outline the pathology and pathogenesis of MASLD-associated liver tumors.

show abstract

Section: Masld-associated Iccamentioning

confidence: 91%